Q-omics provides the consensus-scored SBF1P1 profile across patient tissues and cancer cell-line models. SBF1P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SBF1P1 is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, SBF1P1 RNA expression shows 9,296 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, UCEC, and GBM as cancer lineages where SBF1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SBF1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SBF1P1 survival associations across molecular data types. SBF1P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SBF1P1 RNA expression–survival associations across cancer types. High SBF1P1 expression shows unfavorable associations in LIHC, LUSC and LUAD, but favorable associations in ESCA, HNSC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SBF1P1 RNA expression.
This table summarizes SBF1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for SBF1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SBF1P1 shows lower tumor expression in ESCA and STAD and higher tumor expression in UCEC, COAD, LUSC and KIRP. The UCEC box plot shows higher SBF1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .021).
This table shows molecular features associated with SBF1P1 in patient tissues and cancer cell lines. In patient samples, SBF1P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
